Get the Stockscreener App
100.77
0.05%
-0.05
After Hours:
100.00
-0.77
-0.76%
Rhythm Pharmaceuticals Inc stock is traded at $100.77, with a volume of 640.19K.
It is down -0.05% in the last 24 hours and up +4.73% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$100.82
Open:
$99.94
24h Volume:
640.19K
Relative Volume:
1.07
Market Cap:
$6.69B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-35.86
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
+2.97%
1M Performance:
+4.73%
6M Performance:
+69.22%
1Y Performance:
+102.27%
1-Day Range:
$99.71
$102.17
1-Week Range:
$96.30
$102.92
52-Week Range:
$45.91
$106.52
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
100.77 | 6.70B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Using RSI to spot recovery in Rhythm Pharmaceuticals Inc.July 2025 Fed Impact & AI Based Buy and Sell Signals - newser.com
Is Rhythm Pharmaceuticals Inc. trending in predictive chart modelsIPO Watch & High Return Stock Watch Alerts - newser.com
Is Rhythm Pharmaceuticals Inc. (1RV) stock supported by free cash flowWeekly Market Report & Safe Entry Point Identification - newser.com
Is Rhythm Pharmaceuticals Inc. stock dividend yield sustainablePortfolio Value Summary & High Yield Stock Recommendations - newser.com
Is a relief rally coming for Rhythm Pharmaceuticals Inc. holdersWeekly Trade Analysis & Low Risk High Reward Trade Ideas - newser.com
Rhythm Pharmaceuticals Inc. stock trend forecast2025 Price Targets & Free Technical Confirmation Trade Alerts - newser.com
Rhythm Pharmaceuticals (RYTM) Stock Analysis: A Biotech Powerhouse with 17% Upside Potential - DirectorsTalk Interviews
Long term hold vs stop loss in Rhythm Pharmaceuticals Inc.July 2025 Big Picture & Safe Entry Momentum Tips - newser.com
What analysts say about Rhythm Pharmaceuticals Inc 1RV stockVolatility Index Analysis & Minimize Portfolio Damage with Warnings - earlytimes.in
Should you hold or exit Rhythm Pharmaceuticals Inc. now2025 Top Gainers & Trade Opportunity Analysis - newser.com
What indicators show strength in Rhythm Pharmaceuticals Inc.Weekly Profit Recap & Capital Efficiency Focused Ideas - newser.com
Leo Wealth LLC Has $850,000 Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Is Rhythm Pharmaceuticals Inc. (1RV) stock a safe buy pre earningsCEO Change & Consistent Growth Equity Picks - newser.com
Rhythm Pharma Stock Gears Up For Its Next Move - inkl
How to recover losses in Rhythm Pharmaceuticals Inc. stock2025 Market Outlook & Fast Exit and Entry Strategy Plans - newser.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Is Rhythm Pharmaceuticals Inc. meeting your algorithmic filter criteria2025 Key Lessons & Low Risk High Win Rate Stock Picks - newser.com
Why Rhythm Pharmaceuticals Inc. (1RV) stock could be next leaderWeekly Loss Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Rhythm Pharmaceuticals Inc a good long term investmentEconomic Indicators Overview & Low Risk Capital Growth Plans - earlytimes.in
What momentum shifts mean for Rhythm Pharmaceuticals Inc.July 2025 Reactions & Weekly Hot Stock Watchlists - newser.com
Will Rhythm Pharmaceuticals Inc. rebound enough to break evenRecession Risk & Verified High Yield Trade Plans - newser.com
Using data tools to time your Rhythm Pharmaceuticals Inc. exitJuly 2025 Macro Moves & Intraday High Probability Alerts - newser.com
Is Rhythm Pharmaceuticals Inc. stock cheap at current valuationWeekly Trading Summary & Weekly Stock Breakout Alerts - newser.com
Institutional scanner results for Rhythm Pharmaceuticals Inc.Market Volume Report & Fast Exit/Entry Strategy Plans - newser.com
Should You Expect Robust Growth Potential for Rhythm Pharmaceuticals (RYTM) Ahead? - Yahoo Finance
Is Rhythm Pharmaceuticals Inc. (1RV) stock a buy before earnings resultsJuly 2025 News Drivers & Intraday High Probability Setup Alerts - newser.com
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Bardet-Biedl Syndrome Pipeline 2025: Pioneering Clinical Developments by 8+ Global Leaders – DelveInsight | Featuring Rhythm Pharmaceuticals - Barchart.com
Rhythm Pharmaceuticals stock price target raised by H.C. Wainwright to $110 - Investing.com Canada
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shulman Joseph | Chief Technical Officer |
Sep 02 '25 |
Sale |
105.30 |
16,781 |
1,767,006 |
8,509 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):